BSD Medical Promotes MicroThermX® Microwave Ablation System at Radiological Society of North America (RSNA®) Meeting

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (, a leading provider of medical systems that utilize targeted heat therapy to treat cancer, today announced that the Company promoted the MicroThermX® Microwave Ablation System (MicroThermX®) as part of the technical exhibition at the Radiological Society of North America (RSNA®) meeting, which is the world’s largest annual radiology meeting. The RSNA annual meeting, which is the premier worldwide scientific meeting in radiation oncology, was held in Chicago November 25-30, 2011. There were 58,044 attendees at the meeting, including 9,470 international registrants from more than 100 countries.

“Exhibiting at RSNA allowed BSD to present the Company’s MicroThermX® technology to more radiation oncology professionals than at any other venue. BSD's senior sales and marketing managers also held a number of strategic meetings with leading U.S. and international distributors, including distributors throughout Asia, regarding the Company’s MicroThermX® and hyperthermia product lines,” stated Harold R. Wolcott, President of BSD Medical. "We were pleased with the level of interest in the MicroThermX® shown by both the U.S. and the international medical community."

About RSNA®

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists committed to excellence in patient care through education and research. The mission of the RSNA is to promote and develop the highest standards of radiology and related sciences through education and research. The Society seeks to provide radiologists and allied health scientists with educational programs and materials of the highest quality. RSNA has more than 48,000 members in 137 countries.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.


BSD Medical Corporation
Dennis Gauger, 801-972-5555
[email protected]
fax: 801-972-5930

KEYWORDS:   United States  North America  Illinois  Utah

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Oncology  Radiology  General Health